Three Mass General Brigham Ventures’ Portfolio Companies Nominated for 12th Annual NEVY Awards: NEVYs ‘Survivor’
Congratulations to three Mass General Brigham Ventures’ portfolio companies that have been nominated for the 12th Annual NEVY Awards by the New England Venture Capital Association. The awards recognize and honor top startups and investors who have demonstrated an out-hustle and out-innovate mentality on behalf of the communities they exist within.
CodaMetrix was nominated for the Powerhouse Healthcare IT Company of the Year, as was InStride Health. Brixton Biosciences was nominated in the Emerging MedTech Company of the Year.
The NEVYs honor both early-and late-stage companies, as well as venture capitalists who support them and cover a broad spectrum of the region’s thriving industry clusters. This year, the “Survivor” themed NEVYs will focus on more than 60 nominees across five academies that have adapted to new challenges and opportunities over the past year. The academies are Tech, Tough Tech, Life Science, Healthcare IT, and MedTech.
Last year, Codametrix was also nominated for an NEVY in the Emerging Healthcare Company of the Year category. Conceptualized and developed at Mass General Brigham, the Codametrix platform is used to code cases from multiple specialties. Instride, an active portfolio company of MGB Ventures, focuses on evidence-based, insurance-backed approaches to anxiety and obsessive-compulsive disorder and was developed at McLean Hospital. Brixton Biosciences is a clinical-stage life science company that spun out from Mass General Brigham and is recognized for its novel drug-free injectable Neural Ice™ for pain management.
The winners will be announced on Thursday, December 5 at an in-person event at House of Blues, Boston.